|
Orthologous residues
|
|
IRS1 (human): S312‑p, IRS1 (mouse): S307‑p, IRS1 (rat): S307‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
[32P] ATP in vitro, phospho-antibody, western blotting
|
|
Disease tissue studied:
type 2 diabetes
|
|
Relevant cell lines - cell types - tissues:
MEF (fibroblast) [JNK1 (mouse), homozygous knockout], MEF (fibroblast) [PKR (mouse), homozygous knockout]
|
|
Cellular systems studied:
primary cells
|
|
Species studied:
mouse
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
PKR (human)
|
phospho-antibody, co-immunoprecipitation, transfection of wild-type enzyme
|
|
|
KINASE
|
PKR (mouse)
|
activation of upstream enzyme, co-immunoprecipitation, genetic knockout/knockin of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
palmitate
|
|
|
|
increase
|
|
|
thapsigargin
|
|
|
|
increase
|
|
|
|
|
JNK1 (mouse)
|
|
increase
|
JNK -/- decreases
|
|
TNF
|
|
|
|
decrease
|
|
|
|
Downstream Regulation
|
|
Comments:
insulin resistance
|